Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer.

Background Circulating tumor cells (CTCs) can provide the basis for a liquid biopsy and may guide the use of targeted therapies. We report on unbiased quantification of Her-2 protein expression of CTCs. Patients and methods Her-2 assessment of CTCs was carried out using the CellSearch(®) system in 103 metastatic (M1) and 88 non-metastatic (M0) breast-cancer patients. Expression of Her-2 on CTCs was determined by a manual review and an automated algorithm using Her-2- fluorescein isothiocyanate (FITC) fluorescence of leukocytes to determine the Her-2-expression threshold in each sample. Results Her-2 expression of CTCs varied greatly within and among patients compared with Her-2 expression of leukocytes. In M1 patients, a threshold of 75% of Her-2 positive CTCs in patients with ≥5 CTCs was set. Applying this threshold, 9% of M1 patients with Her-2-negative primary tumors had Her-2-positive CTC status and 29% of M1 patients with Her-2-positive primary tumors had Her-2-negative CTC status. No Her-2 discrepancy was observed between CTCs and primary tumors in M0 patients. Conclusions Our findings demonstrate that Her-2 expression is heterogeneous among CTCs within each patient. We show the feasibility of unbiased quantitative and reproducible assessment of treatment targets on CTCs, opening a path towards personalized treatment.

[1]  I. Tannock,et al.  Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  J. Thiery,et al.  Translating metastasis-related biomarkers to the clinic—progress and pitfalls , 2013, Nature Reviews Clinical Oncology.

[3]  T. Fehm,et al.  Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials , 2012, Cancer and Metastasis Reviews.

[4]  J. Bergh,et al.  Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Ligthart.  Redefining circulating tumor cells by image processing , 2012 .

[6]  F. Solé,et al.  Biomarkers characterization of circulating tumour cells in breast cancer patients , 2012, Breast Cancer Research.

[7]  T. Delozier,et al.  Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. , 2012, The Lancet. Oncology.

[8]  M. Campone,et al.  High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Leon W. M. M. Terstappen,et al.  Unbiased and Automated Identification of a Circulating Tumour Cell Definition That Associates with Overall Survival , 2011, PloS one.

[10]  F. Bischoff,et al.  FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE™ platform. , 2011, Cancer genetics.

[11]  S. Sleijfer,et al.  External quality assurance of circulating tumor cell enumeration using the CellSearch® system: A feasibility study , 2011, Cytometry. Part B, Clinical cytometry.

[12]  M. Mottolese,et al.  HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care , 2011, Clinical Cancer Research.

[13]  C. Sotiriou,et al.  HER2-Positive Circulating Tumor Cells in Breast Cancer , 2011, PloS one.

[14]  Ru-Fang Yeh,et al.  Molecular Biomarker Analyses Using Circulating Tumor Cells , 2010, PloS one.

[15]  J. Bono,et al.  All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  X. Pivot,et al.  Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  H. Iwata,et al.  Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer , 2010, Breast cancer.

[18]  T. Fehm,et al.  Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial , 2010, Clinical Cancer Research.

[19]  Anne-Michelle Noone,et al.  Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  G. Dranitsaris,et al.  Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  A. Goldhirsch,et al.  Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Sanjay Shete,et al.  uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues , 2006, Proceedings of the National Academy of Sciences.

[23]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[24]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[25]  Tanja Fehm,et al.  HER-2 gene amplification can be acquired as breast cancer progresses. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Uhr,et al.  Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. , 2002, International journal of oncology.

[27]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[28]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.

[29]  T. Fehm,et al.  HER2-positive DTCs/CTCs in breast cancer. , 2012, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.